- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
**Financial Performance:** Orchid Pharma's Q1 FY27 revenue grew 15% YoY to INR304 Cr, with EBITDA more than doubling to INR25 Cr, showing recovery from a tough FY26. Gross margin improved to 33% from 30%. **Operational & Strategic Updates:** The 7-ACA backward integration project is on track for its first commercial...
An audio recording of the Analysts/Investors Earnings Call discussing the financial results for the first quarter of Financial Year 2026-27, ended on June 30, 2026, has been uploaded. The call covered both standalone and consolidated financial performance for the period.
Orchid Pharma's Investor Presentation for Q1 FY27 highlights robust financial results. Consolidated revenue for the quarter reached ₹153.13 Cr, growing from ₹138.53 Cr year-over-year. Profitability saw a sharp increase, with consolidated EBITDA at ₹23.98 Cr (vs ₹12.23 Cr YoY) and PAT at ₹8.67 Cr (vs ₹3.83 Cr YoY). This boosted...